Findings of a phase 2b study indicated that use of tildrakizumab was associated with significant improvements in joint and skin manifestations of patients with psoriatic arthritis (PsA), although improvement in symptoms of dactylitis and enthesitis were not observed.
Tildrakizumab may be safe and effective for the treatment of joint and skin manifestations in patients with psoriatic arthritis (PsA), according to study findings published in the Annals of Rheumatic Diseases.
As a chronic, progressive, and inflammatory form of arthritis, treatment to address all the clinical manifestations of PsA remains a significant challenge. Moreover, researchers highlight that chronic joint inflammation and potential joint damage from PsA can impose considerable economic burden.
In the current treatment of PsA, clinical recommendations include the use of conventional systemic disease-modifying antirheumatic drugs (csDMARDs) before other therapies, biological DMARDs targeting tumor necrosis factor alpha before csDMARDs, or either approach.
However, emerging research has shown the promise of targeted therapy against interleukin (IL)-23, a key regulatory cytokine in PsA pathogenesis. Guselkumab, an FDA-approved anti-IL-23p19 subunit antibody that targets IL-23 alone, has been shown to be effective in the treatment of signs and symptoms of PsA.
Seeking to investigate the efficacy of tildrakizumab, also an anti-IL-23p19 subunit antibody which is approved for the treatment of plaque psoriasis, researchers conducted a randomized, double-blind, placebo-controlled, multiple-dose, 52-week phase 2b study.
Patients with active PsA (N = 391) were randomized at 1:1:1:1:1 to receive either tildrakizumab 200 mg every 4 weeks (Q4W) (n = 78); tildrakizumab 200 mg (n = 79), 100 mg (n = 77), or 20 mg (n = 78) every 12 weeks (Q12W); or placebo (n = 79) Q4W.
At week 24, patients receiving tildrakizumab 20 mg or placebo switched to tildrakizumab 200 mg Q12W. The primary efficacy endpoint was the proportion of patients with ACR20 response at week 24.
“Secondary efficacy endpoints were assessed without adjustment for multiplicity,” added researchers. “Safety was evaluated from treatment-emergent adverse events (TEAEs).”
In their findings, 71.4%–79.5% of tildrakizumab-treated patients achieved ACR20 at week 24, compared with 50.6% of placebo-treated patients (all P < .01). Significant improvements in secondary outcomes of patients receiving tildrakizumab versus placebo were also observed:
Responses in patients switched to tildrakizumab 200 mg at week 24 were consistent with treatment from baseline.
Conversely, improvement in dactylitis and enthesitis was not observed, with results indicated by researchers to be mixed for other investigated secondary outcomes. TEAEs and serious TEAEs of all patients through week 52 were comparable among all treatment arms, occurring in 64.5% and 3.3% of cases, respectively.
“These findings demonstrate that treatment with tildrakizumab 200 or 100 mg was more effective than placebo for rates of ACR20/50, DAS28-CRP, MDA, and PASI 75/90/100 responses, as well as improvement in physical function,” concluded researchers. “These results support tildrakizumab phase III clinical development in PsA.”
Reference
Mease PJ, Chohan S, Fructuoso FJG, et al. Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52- week phase IIb study. Ann Rheum Dis. Published online May 13, 2021. doi:10.1136/annrheumdis-2020-219014
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Study Validates Smartphone Analysis for Predicting Obstructive Sleep Apnea
November 29th 2023Findings show breathing sounds recorded by smartphones during sleep at home can reliably identify obstructive sleep apnea, presenting an innovative and accessible alternative to traditional in-laboratory polysomnography.
Read More
Insufficient Data, Disparities Plague Lung Cancer Risk Factor Documentation
September 24th 2023On this episode of Managed Care Cast, we speak with the senior author of a study published in the September 2023 issue of The American Journal of Managed Care® on the importance of adequate and effective lung cancer risk factor documentation to determine a patient's eligibility for screening.
Listen